Register Today!
June 11-13, 2017

Joseph B Martin Conference Center
at Harvard Medical School
Your Subtitle text
Full Conference Schedule
Sunday, June 11. 2017


Updated 06/02/2017
 8:00 am – 8:15 am
ICOO 2017 Opening and Welcome
Co-chairs - Paul A. Sloan, MD; Michael J. Brennan, MD 

8:15 am – 9:15 am
Keynote
Addressing America’s Opioid Crisis: 
How Practitioners Can be Agents for Change
Kana Enomoto

9:15 am – 10:00 am
Effect of Abuse-Deterrent Formulations and Immediate-Release Opioids on Abuse, Overdose and Death from Rx Opioids
Richard C. Dart, MD, PhD

10:30 am – 11:15 am
Evidence for Chronic Opioid Therapy
Charles E. Argoff, MD

11:15 am – 11:30 am
Opiate Use and Over-Prescription in Post-Operative Patients
Eric Chen, MD, PhD

11:30 am – 12:30 pm
Improving Opioid Safety and Access to Quality Pain Care within the VA New England Healthcare System (VISN 1)
Julie Franklin, MD, MPH; Tu Ngo, PhD, MPH

12:30 pm – 1:30 pm
Satellite Symposia: Unmasking Opioid Dependence and Addiction:
How to Recognize This Disease in Patients

(Pechet Room) (Non-CME Event, Lunch Provided by ICOO)

1:30 pm – 2:15 pm 

Looking Both Ways Before Crossing the Street: Assessing the Benefits and Risk of Opioids in COPD
Mellar P. Davis, MD, FCCP, FAAHPM

2:15 pm – 3:00 pm
MeDSS: A Data-Driven Decision Support Tool for Pain Management
Jaya Tripathi; Scott Weiner, MD, MPH, FACEP, FAAEM 

3:00 pm – 3:30 pm
Pain Patient Reported Outcomes as a Predictor of Healthcare Resource Utilization (HCRU)  in Prostate Cancer Patients
Natalie Moryl, MD

4:00 pm – 4:15 pm
Physical Exercise as Supplemental Therapy in Methadone Maintenance Treatment
Christopher Cutter, PhD

4:15 pm – 4:30 pm
Summary/Overview of Opioid Management in Cancer Survivors
Paul A. Sloan, MD

4:30 pm – 5:30 pm
Opioid Management in Cancer Survivors: Emerging and Evolving Challenges
Larry Driver, MD; Dhanalakshmi Koyyalagunta, MD

6:00 pm – 8:00 pm
Special Presentation:
Screening of If Only and Panel Discussion

James Wahlberg; Michael Yebba; Panel: TBA


Monday, June 12, 2017

8:00 am - 9:00 am
KEYNOTE
The Role of ADFs in Curbing Opioid Abuse: 
Can ADFs Reduce Opioid Abuse?
Lynn Webster, MD, FACPM, FASAM

9:00 am - 9:45 am
Treating Pain Without Prosecution: Minimizing the Risk of Prescribing Opioids
Carol Warfield, MD; Benjamin Wish, JD

10:15 am – 10:45 am
VA/DoD Clinical Practice Guideline: Opioid Therapy for Chronic Pain
James L Sall PhD, FNP-BC; M. Eric Rodgers, PhD, FNP-BC
 
10:45 am - 11:45 am
Ketamine Use in Chronic Pain Management
Lucy Chen, MD; Ping Jin, MD, PhD, Jianren Mao, MD, PhD

11:45 am - 12:30 pm
Overview of Cannabinoids & Opioids
Seddon Savage, MD, MS

12:30 pm – 1:30 pm
Scientific Symposia: Abuse Deterrent Formulations of Opioids:
Approval Reform & Findings from Electronic Health Data

Dan Cohen, Paul Coplan, ScD, MBA (Pechet Room) (Non-CME Event, Lunch Provided by ICOO)

1:30 pm - 2:30 pm

Utilizing Precision Medicine Technologies to Avoid and Treat Prescription Opioid Abuse
Lynn Webster, MD, FACPM, FASAM; Ramsay Farah, MD, MPH, FAAP, FACPM, FASAM, CPE, CMRO;
Katrina Lewis, MD, BSc

2:30 pm – 2:45 pm
KFL&A Public Health Action Plan on Opioids: Reducing the Community Opioid Load
Content created by: Kieran Moore, MD, CCFP(EM), FCFP, MPH,  DTM&H, FRCPC
Presented by Paul A. Sloan, MD

2:45 pm - 3:30 pm
Assessment, Treatment, and Outcome of Pain Patients at Risk for Prescription Opioid Abuse: A Naturalistic Study
Stephen Butler, PhD; Stacey McCaffrey, PhD

4:00 pm - 4:30 pm
First Do No Harm: Implementing an Opioid Stewardship Program in a HealthCare System
Douglas Oyler, PharmD, BCCCP; Kristy Deep, MD; Phillip Chang, MD, FACS

4:30 pm - 5:30 pm
Your Name is on the Bottle: Current Opioid Prescribing Litigation Trends
and Risk Mitigation Tools to Protect Yourself, Your Practice and Your Community
Hon. Judge Jodi Debbrecht Switalski, BA, JD

5:30 pm - 6:15 pm
Drug Addiction and the Opioid Crisis: The State and Federal Perspective
New Jersey Governor Chris Christie


Tuesday, June 13, 2017

8:00 am - 9:00 am

KEYNOTE
Tackling the Opioid Epidemic with Science:  
Studies from the Laboratory and Clinic
Sharon Walsh, PhD

9:00 am - 9:30 am
Quantitative Urine Drug Testing Offers Some Novel Insights
Amadeo Pesce, PhD, DABCC

10:00 am - 10:30 am
Tapering Opioids Safely
Paul A. Sloan, MD

10:30 am -11:30 am
To Infinity and Beyond! 
Safe and Effective Titration of Basal and Bolus Opioid Doses
Mary Lynn McPherson,  PharmD, MA, MDE, BCPS, CPE; Kathryn Walker, PharmD, BCPS, CPE

11:30 am – 12:00 pm
Top Three Posters Presented 

12:00 pm
ICOO 2017 Conference Wrap Up
ICOO 2017 Keynotes
 Keynote:
Sunday, June 11, 2017
8:15 am – 9:15 am

Addressing America’s Opioid Crisis: 
How Practitioners Can be Agents for Change

Kana Enomoto

Principal Deputy Administrator
Office of the Administrator
Substance Abuse and Mental Health Services Administration
   Ms. Enomoto has been delegated the functions, duties, and authorities of the Administrator of The Substance Abuse and Mental Health Services Administration (SAMHSA) .

   Ms. Enomoto oversees an agency with four centers and four offices, over 600 employees, and a budget of $3.7 billion. Through data, policy, public education, and grants, Ms. Enomoto and the SAMHSA team advance the agency’s mission to reduce the impact of substance abuse and mental illness on America’s communities. 


   Ms. Enomoto has served as Principal Deputy Administrator and principal advisor to the SAMHSA Administrator on operations, policies, and programmatic activities for the agency since August 2011. Prior to that, Ms. Enomoto served as the Director of the Office of Policy, Planning, and Innovation, where she developed, coordinated, and communicated SAMHSA policies across the full spectrum of mental health and substance abuse issues. From 2005-2009, Ms. Enomoto served as the Principal Senior Advisor to three SAMHSA Administrators, and as the Acting Deputy Administrator between 2008 and 2009. She began her tenure at SAMHSA in 1998 as a Presidential Management Fellow. She began her career in research and clinical services with a focus on minority mental health and trauma. 

   Ms. Enomoto has received awards in recognition of her work, including the Arthur S. Flemming Award, the American College of Mental Health Administration King Davis Award, and the Secretary’s Award for Distinguished Service. 

   Ms. Enomoto earned her bachelor’s degree in psychology and master’s degree in clinical psychology from the University of California, Los Angeles and is a graduate of Harvard University’s Kennedy School of Government, Senior Managers in Government Program.
 Keynote
Monday, June 12, 2017
8:00 am - 9:00 am

The Role of ADFs in Curbing Opioid Abuse:
Can ADFs Reduce Opioid Abuse?


Lynn R. Webster, MD, FACPM, FASAM 
Vice President of Scientific Affairs
PRA Health Sciences 
Past President
American Academy of Pain Medicine (AAPM)
     Dr. Lynn Webster has dedicated more than three decades to becoming an expert in the field of pain management. He is the vice president of Scientific Affairs of PRA Health Sciences and past president of the American Academy of Pain Medicine.

   A leading voice in trying to help physicians safely treat pain patients, Dr. Webster actively works within the industry to develop safer and more effective therapies for chronic pain and addiction. He is board certified in anesthesiology and pain medicine, and is also certified in addiction medicine.

   Dr. Webster lectures extensively on the subject of preventing opioid abuse and criminal diversion in chronic pain patients and has authored more than 300 scientific abstracts, manuscripts, journal articles and a book entitled Avoiding Opioid Abuse While Managing Pain: A Guide for Practitioners, many of which are the basis for training physicians who are studying pain.


   Dr. Webster has played an instrumental role in his industry as a strong advocate for safe and effective
pain resolution methods. The Opioid Risk Tool (ORT), which he developed, is currently used and is the standard in multiple countries and thousands of clinics worldwide. He spends most of his time now developing safer and more effective therapies for chronic pain and campaigning for safer use of medications.  He received his doctorate of medicine from the University of Nebraska and later completed his residency at the University of Utah Medical Center’s Department of Anesthesiology.

   Dr. Webster has been quoted by multiple media sources, including in the Los Angeles Times and The Wall Street Journal, and has given over 250 presentations across the United States and internationally. He is the author of The Painful Truth: What Chronic Pain Is Really Like and Why It Matters to Each of Us (Webster Media LLC).
Keynote
Monday, June 12, 2017

5:30 pm - 6:15 pm

Keynote: Drug Addiction and the Opioid Crisis:
The State and Federal Perspective

Chris Christie
Governor, New Jersey
Chairman of the President’s Commission on Combating Opioid Abuse, Addiction, and Overdose
     Chris Christie was sworn in as Governor of New Jersey on January 19, 2010, and re-elected to a second term on November 5, 2013.

   In late March 2017, Governor Christie was selected as Chairman of the President’s Commission on Combating Opioid Abuse, Addiction, and Overdose. He was tasked with leading the commission whose task is to generate actionable recommendations to the president within 90 days of the creation of the commission.

   Governor Chris Christie signed Executive Order 219 in mid-January 2017 declaring the opioid epidemic a public health crisis in New Jersey. The action required the marshalling of all appropriate resources to combat its harmful effects on state citizens. http://nj.gov/infobank/circular/eocc219.pdf

   Governor Christie has placed a spotlight on changing the conversation on drug addiction and focusing on treatment for those struggling with addiction. In September 2014, Governor Christie and Pastor Joe A. Carter of Newark’s New Hope Baptist Church hosted a summit on drug addiction that served as a call to action and conversation focused on ending the stigma around drug addiction and treatment. Governor Christie has followed through on his commitment to take a smarter and more effective approach focused on treating drug-addicted offenders by signing into law landmark, bipartisan legislation to put in place a state-wide, mandatory drug court program.

   Under Governor Christie, New Jersey has taken on the biggest and toughest challenges with real solutions and bipartisan cooperation. He has implemented an aggressive reform agenda to restore fiscal integrity and accountability to state and local government; lowered New Jersey’s property taxes; reformed treatment for individuals convicted of non-violent drug offenses; and improved public education to ensure every child has access to a quality education.

   A lifelong New Jerseyan, Governor Christie, 53, has a deep affection for and strong commitment to the state in which he has spent his entire life.
Born in Newark and raised in Livingston, Chris has lived in New Jersey his entire life, except to attend college at the University of Delaware. He and his wife, Mary Pat, have been married since 1986 and reside in Mendham, where they are raising their four children, Andrew (born 1993), Sarah (born 1996), Patrick (born 2000), and Bridget (born 2003).

   After graduating college in 1984, Chris attended Seton Hall University School of Law. He graduated in 1987 and joined a Cranford law firm, where he was soon named a partner. He was elected a Freeholder in Morris County, and served as Director of the Board in 1997.

   Christie was named US Attorney for the District of New Jersey in 2002. As the chief federal law enforcement officer in New Jersey, earning praise from leaders in both parties and drawing national attention for his efforts in battling political corruption, corporate crime, human trafficking, gangs, terrorism and environmental polluters.
Keynote
Tuesday, June 13, 2017
8:00 am - 9:00 am

Tackling the Opioid Epidemic with Science:  
Studies from the Laboratory and Clinic

Sharon Walsh, PhD
Professor
Department of Behavioral Science and Psychiatry
Director of the Center on Drug and Alcohol Research
College of Medicine, University of Kentucky
Lexington, KY

   Sharon Walsh, PhD, is a Professor in the Departments of Behavioral Science and Psychiatry, and Director of the Center on Drug and Alcohol Research in the College of Medicine at the University of Kentucky.

   Dr. Walsh earned her MS and PhD from Rutgers University in Behavioral Neuroscience and completed her postdoctoral studies at Johns Hopkins University School of Medicine. She remained at Johns Hopkins for 13 years as a faculty member of the Behavioral Pharmacology Research Unit before leaving at the rank of Professor for the University of Kentucky in 2005. 

   Dr. Walsh’s clinical research is focused on pharmacological issues in opioid and cocaine dependence and has been supported by the National Institute on Drug Abuse, private foundations and the pharmaceutical industry. She has conducted studies on the pharmacodynamic and pharmacokinetic characteristics of opioid treatment agents, including buprenorphine, methadone, LAAM and lofexidine, has conducted abuse liability evaluations of opioid analgesics, and has evaluated potential pharmacotherapies for efficacy and safety in the treatment of cocaine dependence.

   Dr. Walsh was the recipient of the Presidential Early Career award for Scientists and Engineers (1997), the Joseph Cochin Young Investigator Award (2000) and the Betty Ford Award (2010). She has served on numerous review and advisory boards, including grant review panels for NIDA and the VA, advisory panels for the Food and Drug Administration, the National Institutes of Health and American Society for Addiction Medicine. She has served as President of the College on Problems of Drug Dependence and has published more than 90 manuscripts and book chapters on substance abuse.
 ICOO 2017 Conference Times
Saturday June 10, 2017
 Exhibitor Setup 2:30 pm to 5:00 pm
Attendee Registration 2:30 pm to 5:00 pm
Sunday June 11, 2017
Attendee and Exhibitor Registration 7:00 am to 6:00 pm
Conference day begins at 8:00 am -  day ends at 8:00 pm
Monday, June 12, 2017
Attendee and Exhibitor Registration 7:00 am to 5:00 pm
Conference day begins at 8:00 am - day ends at 6:30 pm
Tuesday, June 13, 2017
 Attendee and Exhibitor Registration 7:00am to 1:30pm
 Conference day begins at 8:00 am - 
Conference closes at 12:00 pm
 Exhibit Breakdown 12:00 pm to 4:00pm


Please bookmark this page and check back periodically.
Schedule Subject to change without notice